David T. Yeung

Room 7E.314, Royal Adelaide Hospital Port Road
Adelaide, SA 5000, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 131 publications

The partner gene modulates response to asciminib in ABL1-rearranged Acute Lymphoblastic Leukemia.

The partner gene modulates response to asciminib in ABL1-rearranged Acute Lymphoblastic Leukemia.

Journal: Neoplasia (New York, N.Y.)

Published: April 21, 2026

Mitochondrial DNA mutations are associated with impaired oxidative phosphorylation and enhanced imatinib response in chronic myeloid leukemia.

Mitochondrial DNA mutations are associated with impaired oxidative phosphorylation and enhanced imatinib response in chronic myeloid leukemia.

Journal: HemaSphere

Published: March 18, 2026

Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinib.

Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinib.

Journal: Leukemia

Published: March 10, 2026

Allosteric and ATP-Pocket BCR::ABL1 Inhibition In Vitro, and Characterising Ex Vivo Thrombo-Inflammatory Biomarkers and Thrombin Generation in Asciminib-Treated CML Patients.

Allosteric and ATP-Pocket BCR::ABL1 Inhibition In Vitro, and Characterising Ex Vivo Thrombo-Inflammatory Biomarkers and Thrombin Generation in Asciminib-Treated CML Patients.

Journal: International journal of molecular sciences

Published: March 02, 2026

The gastrointestinal microbiome and constituent short-chain fatty acids: a narrative review of an underexplored axis in acute lymphoblastic leukemia.

The gastrointestinal microbiome and constituent short-chain fatty acids: a narrative review of an underexplored axis in acute lymphoblastic leukemia.

Journal: Gut pathogens

Published: February 24, 2026

Allogeneic stem cell transplantation for mantle cell lymphoma can achieve durable remission and myeloablative conditioning is associated with inferior survival: an Australian and New Zealand Transplant & Cellular Therapies registry study.

Allogeneic stem cell transplantation for mantle cell lymphoma can achieve durable remission and myeloablative conditioning is associated with inferior survival: an Australian and New Zealand Transplant & Cellular Therapies registry study.

Journal: Internal medicine journal

Published: February 01, 2026

Central nervous system involvement in acute lymphoblastic leukemia: pathogenesis and targeted therapy.

Central nervous system involvement in acute lymphoblastic leukemia: pathogenesis and targeted therapy.

Journal: Leukemia

Published: December 17, 2025

Inequalities in the provision of guideline-directed medical therapy following myocardial infarction: a cohort study.

Inequalities in the provision of guideline-directed medical therapy following myocardial infarction: a cohort study.

Journal: BMC cardiovascular disorders

Published: December 16, 2025

Underreported and underreviewed: Addressing the gaps in TKI tolerability literature for chronic myeloid leukemia.

Underreported and underreviewed: Addressing the gaps in TKI tolerability literature for chronic myeloid leukemia.

Journal: Blood reviews

Published: December 09, 2025

Long-Term Survival Gains after Allogeneic Hematopoietic Stem Cell Transplant are Driven by Reductions in Non-Relapse Mortality: A 35-Year Statewide Australian Cohort Study.

Long-Term Survival Gains after Allogeneic Hematopoietic Stem Cell Transplant are Driven by Reductions in Non-Relapse Mortality: A 35-Year Statewide Australian Cohort Study.

Journal: Transplantation and cellular therapy

Published: November 13, 2025

Identification of a Novel, Oncogenic and Targetable TPR::ABL2 Fusion Gene in T-Cell Acute Lymphoblastic Leukaemia.

Identification of a Novel, Oncogenic and Targetable TPR::ABL2 Fusion Gene in T-Cell Acute Lymphoblastic Leukaemia.

Journal: EJHaem

Published: October 30, 2025

The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia.

The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia.

Journal: British journal of haematology

Published: September 14, 2025

Showing 1-12 of 131

Last Updated: 09/26/2026